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Tumors in Space is a cutting-edge cancer research experiment at the intersection
of stem-cell biology and space technology selected by the United Nations Office for
Outer Space Affairs and the China Manned Space Agency for a 31-day space mission
on board the China Space Station. Anchored in Norway, Tumors in Space includes
an international team of exceptional scientists at several European partner organi-
zations including the University of Oslo and the Norwegian University of Science
and Technology in Norway, the International Space University in France, the
Belgian Nuclear Research Center in Belgium, and Vrije University Amsterdam as
well as the Hubrecht Institute in The Netherlands. This chapter first presents our
two novel hypotheses including the current state of scientific evidence upon which
our hypotheses are based. Following, the seven main steps of our spaceflight
preparation are discussed within the context of our 2025 launch date from China.
Finally, some thoughts on impact, including support for the United Nation’s Sus-
tainable Development Goals and commitment to science communication in the
public domain, are given. Tumors is Space is under a programme of, and funded by
the European Space Agency with the support of the Norwegian Space Agency.
Keywords: China Space Station, cancer, organoids, microgravity, cosmic radiation
1. Introduction
Spaceflight is a high-risk/high-gain endeavor (Figure 1) that is resource inten-
sive. For these reasons, spaceflight experiments are rare, and selection is highly
competitive at the international level. Selection criteria for spaceflight experiments
include scientific excellence, innovation, feasibility, impact, competency of the
scientific team to achieve the proposed research goals, and timely delivery. More-
over, a selected spaceflight experiment must be novel in that it must address a
critical issue for which knowledge and understanding are lacking; it must be
ground-breaking in nature, both literally and figuratively. In the case of medical
research in space, a selected spaceflight experiment must create value for astro-/
cosmo-/taikonaut health applied to short- and long-duration space missions and
solar system exploration. At the same time, space medicine must also bring value to
public health on Earth. In this vein,Tumors in Space is a ground-breaking cancer
research experiment at the intersection of space technology and stem-cell biology
recently selected for a 31-day space mission on board the China Space Station (CSS).
Not only will Tumors in Space address cosmic radiation as a potential cause of
cancer for humans in space, it will also address the side effects of radiation therapy
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for cancer patients on Earth. In addition to radiation biology experiments,Tumors in
Space will exploit the microgravity environment on the CSS to investigate whether
lack of gravity can slow or stop the growth of cancer. Like all selected spaceflight
experiments,Tumors in Space will undergo several years of preparation before
spaceflight launch. This preparation period is broken down into seven main steps
over 6 years, culminating in our spaceflight experiment scheduled for a 2025 launch
date out of China. This chapter will discuss the different steps of our spaceflight
preparation as depicted in Figure 2.
In addition to these seven steps, other important aspects of Tumors in Space
will be presented, namely, the scientific background upon which the hypotheses
are built, team structure and expertise, the importance of impact including
response to the United Nations Sustainable Development Goals, and science
communication in the public domain. Let us first begin with a presentation of the
problem statement and the supporting evidence upon which the Tumors in Space
hypotheses are built.
2. The problem statement and supporting evidence
As stated in Section 1, medical experiments in space must address crew health
and safety while simultaneously bringing value to medicine on Earth. What follows
is a short paragraph on the burden of cancer on Earth, followed by a second
paragraph on space radiation risk for crewed missions. To end this section, evidence
on the potential use of microgravity for cancer therapeutics will be given.
Figure 1.
Spaceflight is high risk and high gain.
Figure 2.
Tumors in Space project timeline over a 6-year period from 2020 to 2025 and according to seven steps of
spaceflight preparation including launch to China Space Station and safe return to Earth in 2025.
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Interspersed throughout this section are some details on our scientific approach,
more of which will be detailed later in this chapter.
The cancer burden on Earth is substantial. Currently, cancer is the second
leading cause of death worldwide [1]. As of 2018, an estimated 18.1 million people
had been diagnosed with cancer, and nearly 10 million people had died from the
disease [2]. Moreover, new cancer cases are expected to increase by 70% over the
next two decades [1]. As of 2009, the global cost of treating cancer patients was
estimated to be $285.8 billion USD per year, and the indirect costs associated with
premature death and loss of productivity was estimated at $1.16 trillion USD per
year [2]. Over time, these costs will continue to rise.
The scientific community has made increasing progress toward understanding
lifestyle, environmental, and genetic causes of cancer [3], yet approximately 50% of
all cancer cases have no known cause. There is no cure for cancer. We must
therefore adopt a broad, interdisciplinary perspective and exploit all scientific and
technical capabilities to better understand this disease, including the use of orbital
platforms [4]. Tumors in Space will exploit the natural spaceflight environment on
the China Space Station to address cosmic radiation as a potential unknown cause of
cancer among crew and to harness microgravity as a potential source for cancer
therapy in space and on Earth.
In space, radiation risk is the most dangerous issue for crew health and safety.
The spaceflight environment is characterized by high atomic number energy
(HZE1) ions from three natural sources of radiation that could lead to crew sickness
or death [5]. During space exploration missions, crew are exposed to HZE ions from
trapped particle belts, solar particle events, and background galactic cosmic rays
[5]. When primary HZE ions interact with spacecraft materials, they can generate
harmful secondary radiation that can penetrate deeply into the human body. Cancer
risk from human spaceflight and exploration is assumed to be high, but the short-
and long-term effects of harmful HZE ion radiation during deep space missions are
still undetermined and have large uncertainties [5]. As stated by the European
Space Agency (ESA), most of this uncertainty is due to poor knowledge on the
effects of galactic cosmic rays [6]. Tumors in Space will address some of the uncer-
tainty associated with cosmic radiation as a potential cause of cancer among crew.
At the same time, advances in space-based cancer research have the potential to
improve charged particle therapy in oncology for the benefit of cancer patients on
Earth.
All cancers are caused by somatic mutations, meaning an accumulation of
genetic alterations that damage our deoxyribonucleic acid (DNA) at the cellular
level [7]. Cell damage from exogenous exposures (e.g., HZE ion radiation), as well
as endogenous exposures (e.g., circulating hormones), and modifications to DNA
can lead to cancer. DNA damage in cancerous cells can be observed as distinct
patterns known as mutational signatures. Just like fingerprints are unique to every
individual, mutational signatures are unique to specific cancer-causing exposures.
Each mutational signature is the outcome of a series of biological processes that
include DNA modification or damage, DNA repair or absence of repair, and DNA
replication. Using cancer genome sequencing [8], these mutational signatures can
be observed, catalogued, and compared to identify unique causes of different can-
cer types. This was first demonstrated when mutational signatures specific to UV2
1 The abbreviation HZE comes from high (H) atomic number (Z) and energy (E).
2 UV stands for ultraviolet rays from sunlight that induces a unique mutation found specifically in skin
cancer.
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exposure from the sun were observed in the p53 tumor suppressor gene3 [9]. Most
cancer genomes are now characterized by multiple mutational signatures across
multiple mutational processes that generate more than one somatic mutation in
each cancer cell [10]. This evidence leads us to our first Tumors in Space hypothesis.
Hypothesis 1: We will identify a novel mutational signature of cosmic radiation
in healthy and cancer human organoids after 31-days exposure to cosmic radiation
in space. The mutational signature of cosmic radiation can then be used as a
biological marker for early detection of cancer and cancer susceptibility among
spaceflight crew.
Beyond cosmic radiation, the space environment provides unique microgravity
conditions that Earth-bound laboratories can simulate but never replicate. Micro-
gravity can be exploited to study biological mechanisms and pathways to improve
our understanding of many diseases, including cancer. Previous spaceflight experi-
ments have shown that exposure to the space environment alters immune cell
growth and function [11], causes cytoskeleton and cell shape changes [12], and
alters cellular gene expression including genes involved in replication and suppres-
sion of tumors [13, 14]. This brings us to our second Tumors in Space hypothesis.
Hypothesis 2: Exposure to microgravity during a 31-day space mission will slow
or stop the growth of cancer.
We will conduct a tumor colony survival analysis which is as simple as counting
the number and/or expansion of our organoids after long-term exposure to micro-
gravity and then compare those results to our ground-based controls. It is crucial to
block out cosmic radiation that may interfere with this microgravity experimental
arm. For that reason, we are building radiation shielding to ensure the cancer
organoids exposed to microgravity are not hit by cosmic radiation.
So, the China Manned Space Agency (CMSA) in collaboration with the United
Nations Office for Outer Space Affairs has selected Tumors in Space for a 31-day
space mission on board the China Space Station (Figure 3). Tumors in Space utilizes
space technology and three-dimensional (3D) organoid technology (see further) to
study early mutational events in human DNA due to spaceflight exposure. We
Figure 3.
Artist rendition of the China Space Station (credit: China Manned Space Agency).
3 The p53 gene provides instructions for building a protein that acts as a tumor suppressor. Well-
characterized mutations in this gene have been attributed to UV exposure and are found in many types
of skin cancer.
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expect to find a unique mutational signature of cosmic radiation. We also expect
that cancer organoid growth will slow or stop after exposure to microgravity.
3. Going beyond state of the art
As mentioned previously, excellent science in line with the current state of
evidence does not fulfill the stringent selection criteria for spaceflight experiments.
Space medicine research must be novel, go beyond current scientific paradigms,
and have application to crew health in space and public health on Earth. In other
words, selected space medicine experiments must go beyond state of the art.
Not only does Tumors in Space more than double the mission length of all
previous cancer experiments in space, we also use the most advanced and physio-
logically relevant bio-samples in our experiments—human organoids. Until now the
term “organoids” has been introduced without explanation. In fact, organoid tech-
nology is so new that many scientists are unfamiliar with the term. So, what exactly
is an organoid, and why is an organoid so much more advanced than a cell line that
is typically used in medical research?
Human organoids are multicellular, stem-cell-derived, 3D constructs that self-
organize to mimic the structure and function of the source tissue [15]. More simply,
a human organoid is a 3D clump of human cells and extracellular matrix, taken as a
biopsy from living human tissue, but organoids “live” in a lab. What is amazing
about organoids is that they can be expanded, cloned and cared for in a way that
allows them to replicate and grow while retaining the structure and function of the
original source tissue or organ. For example, a colon cancer organoid derived from a
tumor biopsy taken (with permission) from a colon cancer patient will not only
grow into a 3D structure under laboratory conditions; it will also behave like we
would expect colon cancer to behave. Same goes for healthy tissue.
Figure 4 shows an artist rendition of the growth of a colon organoid. A small
sample, or biopsy, is taken from the colon tissue of a patient. Both the original colon
tissue and the biopsy are 3D in nature. Once the biopsy is removed from the patient,
it can be nurtured in the lab so that cell division continues, resulting in larger and
Figure 4.
Artist rendition of colon organoid growth (credit: Hans Clevers, the HUB).
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more complex tissue samples that mimic the structure and function of the source
tissue (in this case, the human colon). Organoids are much smaller than the organ
they mimic but can be up to 5 mm in size. These organoids are the most advanced
and physiologically relevant bio-samples available for medical research today. This
means that we can conduct cutting-edge cancer research using human organoids
rather than cell lines.
Although monolayer cancer cell lines are easily accessible, well understood, and
used in all previous cancer experiments in space, they lack spatial cellular organi-
zation and physiological relevance [16]. Cell lines cannot mimic conditions found in
real humans, whereas organoids can. Using human organoids ensures that our
results are applicable to patient diagnosis and treatment. This is crucial since we
need to get as close as possible to studying the real human body in space. Organoid
technology bridges the gap between cell lines and humans, or in vitro and in vivo. In
2017, organoids were named Method of the Year by Nature Methods for their
unparalleled potential to advance our understanding of human biology, especially
cancer [17]. We are the first team to send healthy and cancer human organoids
into space.
4. International collaboration
Before we dig into the seven steps of preparation for our spaceflight experiment,
a quick note on international collaboration is warranted. Success of such a complex
space medicine experiment requires world experts across many different fields.
Figure 5 is color coded to show collaborating countries, not only according to levels
of responsibility with regard to the project but also according to geopolitical
boundaries. You can see from Figure 5 that Norway (in light gray) and China (in
dark green) stand apart from the other collaborating countries like the Netherlands,
Belgium, and France (in dark blue).
Norway, the center of the figure, is the coordinating country because this is
where the principal investigator is located, along with the several members of the
Tumors in Space team. We also have the support of the Norwegian Space Agency.
Furthermore, Norway has identified China as a priority country for technical and
scientific collaboration—for example, in satellite and broadband communication, as
well as medicine. Norway and China are united by an underlying cooperative effort
for the Tumors in Space collaboration. China is the host country for the Norwegian
Tumors in Space experiment that has been selected for a 31-day space mission on
board the China Space Station.
Figure 5.
Tumors in Space collaborating countries.
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Our additional collaborators are based in Europe and are part of the European
Union. The Netherlands is a collaborating country where two critical organizations
are located. Firstly, our patient-derived organoids come from Hubrecht Organoid
Technology (the HUB) in Utrecht, and some of our ground-based experiments will
take place at the European Space Research and Technology Center of ESA in
Noordwijk. Our radiation biology experts are located in Belgium at the Belgian
Nuclear Research Center where our ground radiation experiments in preparation
for spaceflight will be conducted. Not only do they house safe infrastructure for
radiation biology experiments, our Belgian colleagues have years of space experi-
ence and substantial experience in the safe design of nuclear reactors. For the latter
reason, our Belgian colleagues will also participate in the design and development of
our spaceflight hardware in close collaboration with Norway and China. Finally,
France is the location of the International Space University, to which the principal
investigator and other Tumors in Space team members are affiliated. Our aircraft
parabolic flight campaigns will also be flown from France.
This brief summary shows how important international collaboration is. With-
out all of these partners, realizing the most advanced cancer experiment ever
conducted in space would not be possible. It is because of the unique strengths and
expertise of all collaborating partners that the Tumors in Space project has become a
reality.
5. The Tumors in Space experiment in seven steps
The step-by-step preparation of our spaceflight experiment is now described.
Each one of these steps could be a chapter in itself. Certainly, some details must be
omitted. The success of this entire project relies heavily on the success of each step,
both independently and collectively.
5.1 Ethics, regulatory affairs, and information management: step 1
This step ensures proper procedures for the selection, release, and use of
intraindividual healthy and cancer organoids according to biobanking protocols and
informed consent procedures. Procedures and consents are subject not only to the
approval of the HUB biobank in the Netherlands but also from the host institute in
Norway, as well as our collaborating institutes where our organoid research will be
conducted (the European Space Agency in the Netherlands, the Belgian Nuclear
Research Center in Belgium, parabolic flight laboratory in France, and the China
Manned Space Agency in China for our spaceflight). Each institute has its own
procedure, and each country or set of countries have their own legislations. Ship-
ping bio-samples involves material transfer agreements and customs paperwork,
and since human organoids contain human DNA, special ethical requirements
apply.
First and foremost, all patients provide written, informed consent to the HUB
for future use of their bio-samples in medical research according to very specific
guidelines. Research ethics approval for each experiment is required from the HUB
and from the host institute in Norway. No experimentation can begin without
these ethics approvals that assess our intended use of the samples across all of our
collaborating sites in Europe and China. Since the HUB biobank is located in
Europe, many of the intricacies with regard to ethics and legislation across our
European collaborating sites are already in line. However, human DNA can be
imported, but not exported from China. This means that we can ship our
organoid samples into China in preparation for our spaceflight launch, but after our
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spaceflight experiment has been conducted and safely returned to Earth, those
same samples cannot be exported to our genomics laboratory in Norway.
Consequently, laboratory analysis of our spaceflight samples must be conducted
in China, after which time the organoid samples will need to be destroyed and
the data will need to be transferred to Norway for bioinformatic and statistical
analysis.
5.2 Laboratory, bioinformatics, and statistical analysis pipelines: step 2
In this step, we go from human organoids in a lab that have been exposed to
radiation (ground and space) and/or (micro)gravity (ground and space) to labora-
tory methods at the Genomics Core Facility (GCF) housed in Norway. We then
treat the “big data” with bioinformatics tools to break down the noise and scale
down the data for statistical analysis. It is important to note that the details in this
step are given at the time of writing in March 2020. Genomics as a field is constantly
advancing, sometimes exponentially, and so are the tools used to work with the
samples and analyze the data. That being said, our Tumors in Space experimental
methods are still being finalized, but this at least gives you a glimpse into our
preparation for spaceflight.
Organoid sample selection: To account for tissue heterogeneity and differences in
mutational signatures, we will use paired samples from three different patients.
Assuming 7–10 subclones from each starting culture, we would have 21–30 paired
samples which will give sufficient statistical power to detect consistent differences
in mutational signatures. Subcloning is an essential step for this experimental strat-
egy, as subcloning ensures that mutations occurring prior to subcloning will be
fixed in subsequent culture, allowing these mutations to be detected by whole
genome sequencing and somatic genotyping.
Organoid cell culture and subcloning: Laboratory procedures will be handled by
the Genomics Core Facility at the Norwegian University of Science and Technology
(NTNU) in accordance with previously published methods [18]. The CGF provides
state-of-the-art high-throughput genomics technology including sequencing and
genotyping microarray analysis. The major advantages of using the CGF include
highly experienced staff and the use of robotics. Tumor organoids must be cultured
in specifically designed medium [18]. After a fixed exposure time, subclones from
each source organoid will be cultured for an additional fixed number of cell divi-
sions to allow for the occurrence of random mutations before whole genome
sequencing and somatic genotyping [19].
Whole genome sequencing and somatic genotyping: Classic sequencing-based whole
genome analyses of mutational signatures (healthy vs tumor tissue) rely on muta-
tions being clonally expanded due to tumor growth, i.e., the mutation occurred in
an ancestor cell so that all daughter cells will have this mutation, and the mutation is
detectable if a sufficiently large percentage of the tumor cells share this mutational
ancestry. Clonal expansion ensures that within an organoid sample, there will be
several DNA fragments and sequencing reads that share the same mutation. In this
manner, mutations can be distinguished from sequencing errors. This also means
that the mutations occurring within the tumor organoid source cells will not be
detectable, as these mutations have not yet been amplified by cell division (unless
the same mutation occurs at the exact same nucleotide within a sufficiently large
subset of the current cells). The sequencing depth determines the percentage of
cells that need to share mutations in order to be detected. For example, 100x
sequencing depth can detect mutations if the mutations are present in 5% of cells,
whereas 1000 sequencing depth can detect mutations present in only 0.5% of
cells.
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Although polymerase chain reaction (PCR4) is a widely used approach, we
cannot use this approach for the current study. Even if we increase the sequencing
depth to 5x the number of cells, we would get PCR-amplified copies of the DNA in a
single organoid sample and would not be able to distinguish PCR errors from
mutations. However, with rolling circle amplification, we would always use the
same original (circularized) DNA fragment as a template for amplification. In this
way, we will have a long DNA fragment with multiple copies of the original DNA
fragment, and by sequencing these copies in a single read, we will detect mutations
as consistent changes within each copy.
Bioinformatics and statistical analysis pipeline: All somatic changes in whole
genome data will be analyzed with mutation calling pipelines developed in Norway.
Healthy tissue more than 5 cm from the tumor and consisting of epithelial and
connective tissue [18] will be used as the “germline” reference. Mutations consid-
ered to be germline will be removed. Mutational signature extraction using non-
negative matrix factorization will be performed [20]. Signature attribution in
reference to the Catalogue of Somatic Mutations in Cancer [10] and the Pan-Cancer
Analysis of Whole Genome [21] will be conducted.
5.3 Spaceflight hardware readiness: step 3
In this step, we are designing, developing, testing, and validating an automated
cell culture experimental unit and six-paneled tantalum cover for cosmic radiation
protection. Several characteristics make tantalum a good choice for radiation protec-
tion, all of which will be presented below. We will use our ground-based platforms, a
sounding rocket, and aircraft parabolic flights to test the impact of environmental
stressors and operational constraints (e.g., vibration, changes in gravity, changes in
temperature, experimental lag time) on the fidelity of our organoid culture technique
and the readiness of our spaceflight hardware. Our spaceflight hardware must fit
according to requirements and constraints of the biological research module on the
China Space Station. Other experimental equipment that we need for our experiment
will be hosted by the China Space Station including a temperature-controlled incuba-
tor/cooler and a 1 g centrifuge or variable gravity rack. We also need dosimeters to
measure radiation levels for the duration of our experiment.
Experimental unit: We are designing and developing a biocompatible-automated
organoid culture experimental unit. An essential first step is to complete biocom-
patibility testing for each material required for the construction of the unit. Direct
contact between organoid culture medium and experimental unit materials must
not attenuate organoid growth. More specifically, for our experimental unit to be
deemed biocompatible, 75% of all organoid samples must survive. Our unit is
required to be operational for the full duration of the 31-day experiment, including
automated nutrient solution exchange on days 6, 12, 18, and 24. Our unit must
adhere to a standard temperature profile (18–38°C for organoid growth, 4°C for
fixed samples) and CO2 saturation level (5%). Finally, our unit must be capable of
enduring physical stressors (vibration, g-forces) while maintaining organoid cul-
ture and survival.
We cannot procure market-ready experimental units because all previous cancer
experiments in space have used 2D monolayer cancer cell lines and Tumors in Space
uses 3D human organoids. However, units used for previous cancer experiments in
4 PCR is a widely used molecular biology method that makes millions to billions of copies from a DNA
sample, allowing amplification of a very small amount of DNA to a larger amount of DNA for a detailed
study.
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space do provide us with a good foundation for our own design and development.
For example, Grimm’s lab first tested their own cancer cell line experimental unit
during the Shenzhou-8 mission [22], which was then further improved for the
SpaceX CRS-8 ISS mission [23]. Grimm’s unit sets the standard for safe cell culture
and cell nourishment followed by fixation according to a pre-programmed
timeframe. From this foundation, we are designing our experimental unit with
built-in pre-programmed electronics to control temperature gradients for organoid
cell culture medium, as well as automated oxygen, carbon dioxide, and nutrition
cycles to keep our organoids alive for the duration of the 31-day space mission.
A small temperature-controlled incubator/cooler with a rack insert: Our experi-
mental units will be fully automated removable inserts designed to interface with a
small temperature-controlled incubator/cooler that serves as a miniature laboratory
for self-contained, automatic microgravity experiments on cells/organoids—
similar to ESA’s Kubik5 on the International Space Station (Figure 6) [24]. This
equipment will be hosted by the China Space Station. The rack insert of the
incubator/cooler will provide passive structure to house our experimental unit. The
incubator/cooler will operate between 4°C and 38°C and will permit a 1 g centrifuge
insert to allow for simultaneous experiments with 1 g control samples and
microgravity samples.
Onboard 1 g centrifuge or variable gravity rack: To thoroughly test our hypotheses
and delineate compound spaceflight exposures (microgravity and cosmic radia-
tion), we also require an onboard 1 g centrifuge or variable gravity rack that will
allow us to expose our organoids to only cosmic radiation while maintaining the
standard gravitational force felt on Earth (1 g). Our organoid medium can stay at
37°C, while in the centrifuge, our experimental unit will fit the standard payload
boxes hosted by the China Space Station. A variable gravity rack which contains a
centrifuge with rotating containers for biological and fluid experiments [25] may be
larger than the standard 1 g centrifuge available within the incubator/cooler insert
rack. Either the smaller 1 g centrifuge or the larger variable gravity rack will be used
for our experiment, and this decision will be taken in close collaboration with the
China Manned Space Agency during our hardware development phase.
Tantalum cover for experimental unit: In order to test whether exposure to
microgravity slows or stops the growth of cancer, we need to protect our organoids
from cosmic radiation exposure. To do so, we are designing a six-sided radiation
shield to cover all sides of our organoid cultivation chamber in order to shield the
organoids from cosmic radiation. The size, shape, and mass of the tantalum cover
Figure 6.
Kubik on the ISS (credit: ESA).
5 Kubik (from Russian for cube) is a miniaturized laboratory in a 40 cm cube, installed in the ESA orbital
laboratory Columbus module on board the ISS, and is used for several kinds of biology experiments in
space.
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are being designed according to the size and shape of our experimental unit and the
mass constraints of the payload. Several characteristics make tantalum a good
choice for radiation shielding of biological experiments in space including very good
biocompatibility, excellent corrosion resistance, and very high melting point.
Tantalum can also be easily welded into the required shape and size.
Dosimeters: We also need electronic dosimeters to provide passive reading of
radiation dosage for the duration of the 31-day experiment. The dosimeters must be
sensitive enough to measure high-energy cosmic radiation, lightweight, and com-
pact yet durable enough to be operational in the spaceflight environment [26]. The
dosimeters must provide tissue equivalent readings. This means that the electronic
data must provide the same information about cosmic radiation dose as we would
expect if human tissue, rather than the dosimeter, was directly exposed.
We will work in close collaboration with the China Manned Space Agency to
develop, assemble, and test spaceflight hardware according to CMSA standards
and quality controls with particular attention to interface compatibility, mass,
size, power requirements, and duration of experiment. We will also test our
spaceflight hardware during our ground, sounding rocket, and parabolic flight
experimental arms.
In preparation for spaceflight, we are running several experiments on research
platforms including ground-based space analogues that will produce effects on our
organoid models similar to those experienced in space. This includes radiation
facilities for ionizing and heavy ion irradiation and the random positioning machine
(RPM) to simulate microgravity. It is important to remember that the spaceflight
environment can be simulated but never replicated on the ground. We are also
preparing for experiments on a sounding rocket and during aircraft parabolic
flights. These preparatory experiments are essential to ensure a successful experi-
ment in space. Not only will our organoid cultures and hardware development be
tested, but we will also collect important baseline data for later comparison to our
spaceflight data. In addition, we will have the opportunity to standardize our
shipping, handling, and storage procedures for the organoids, as well as define our
laboratory, bioinformatics, and statistical analysis pipelines. Finally, our ground
radiation work does not only provide us with a mutational signature of different
types of radiation for later comparison with cosmic radiation; it is designed to better
understand the side effects of radiation therapy for cancer patients on Earth.
5.4 Ground experiments: step 4
We are using ground-based facilities at the Belgian Nuclear Research Center and
ESA’s European Space Research and Technology Center to test our hypotheses and
theoretical approach and to refine our methodology and operational procedures in
preparation for spaceflight. We will collect baseline data on the mutational signa-
ture of ionizing and heavy ion radiation and use the random position machine
(RPM) to test whether simulated microgravity stops or slows the growth of cancer.
Ionizing radiation: To identify a unique mutational signature of cosmic radiation,
we must verify the mutational signature of ionizing and heavy ion radiation for
comparison. Using the gamma beam irradiator at the Belgian Nuclear Research
Center, we will irradiate the following:
i. Our 1 g control samples
ii. Our samples exposed to simulated microgravity in the RPM
iii. Our experimental unit and tantalum cover
11
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Our 1 g control samples can be placed in direct line of the gamma ray to capture
the mutational signature of ionizing radiation. By varying the dose and time of the
beam, we will simulate radiation therapy given to cancer patients on Earth and
examine whether healthy organoids from cancer patients turn cancerous after dose-
and time-dependent exposure to radiation. Next, our organoids will be contained in
the RPM, and the RPM will then be placed in front of the irradiator. This will allow
us to simultaneously expose our organoids to radiation and simulated microgravity.
Finally, we will test the fidelity of our spaceflight hardware by exposing our
organoids housed within the experimental unit and protected by the tantalum
shielding to a predetermined dose rate of ionizing radiation.
The random position machine: We are using the RPM at ESA-ESTEC to collect
baseline data on the effect of simulated microgravity on the growth of cancer
organoids. The RPM (Figure 7) uses two rotating axes, each with independent
motor drives running at random speeds and generating random three-dimensional
movements [27, 28] that change the direction of the gravitational vector felt by the
organoids such that cumulative gravitational effects are cancelled over time. The
maximum angular speed of the inner and outer frame of the RPM generally ranges
from 20°/s to 120°/s. Thus, the geometry and size of the container within which the
biological system is placed must be carefully considered [29]. The sample container
will then be mounted to the inner axis. The RPM can run for the 31-day duration of
the experiment, and cultural medium can be replaced when needed.
5.5 Sounding rocket: step 5
We will use a sounding rocket to test the impact of environmental and opera-
tional factors (e.g., vibration, changes in gravity, changes in temperature, experi-
mental lag time) on the fidelity of our models and readiness of our hardware.
Sounding rockets carry experiments up to 750 km above the Earth’s surface and
offer up to 13 min of microgravity. After launch, the sounding rocket motor is shut
down, and our experiment will be in free fall. Parachutes are deployed on the
downward arc to return the rocket and experiments safely to the ground. The
rocket and experimental unit will reach a peak gravitational force of 12 g which
could impact our organoids, as can launch vibrations and other environmental
factors. This will be our first microgravity experiment. Not only will we collect
valuable data on the underlying gene expression of our organoids after exposure to
microgravity, we will also have the opportunity to test our hardware as part of a
rocket launch. At the end of this step, we will use the data to improve our logistics
and operations, our organoid models, and the fidelity of our spaceflight hardware.
Figure 7.
The RPM at ESA-ESTEC (credit: ESA).
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5.6 Parabolic flights: step 6
Similar to the sounding rocket, we will use aircraft parabolic flights to test the
impact of environmental and operational factors on our experiment. The parabolic
flight takes place on a specially designed commercial aircraft [30] that flies through
a series of parabolas and gives 20–22 s of microgravity on each parabola. The
aircraft flies up and down at 45° angles, and at the top of the curve, 20–22 s of
microgravity is experienced. About 2 g is experienced during ascent and descent. A
typical parabolic flight campaign involves 30 parabolas per flight and 3 flights over
a 1-week period. This will be our final step before spaceflight and our last opportu-
nity to make any and all necessary improvements to our experiment.
5.7 Spaceflight experiment: step 7
According to standard operating procedures and in close collaboration with the
China Manned Space Agency, we will finalize our preparation for spaceflight in the
following manner. Our experimental units will be assembled prior to launch,
including several backup units. All hardware will be sterilized and approved for
launch. Our samples will be transported to the launch site on dry ice from our
biobank in the Netherlands. Our organoids will arrive a minimum 7 days before the
launch. After the initial phase of growth, our organoids will be placed into the
validated and approved units, and the units will be inserted into the incubator/
cooler. The incubator/cooler housing our units will be loaded into the rocket prior to
launch (-1 hour to -2 days). Once the payload is ready for flight, no additional
handling of the experiment will be required before launch.
The experiment will start and end under constant environmental conditions
(e.g., temperature, pressure, humidity) after our experimental units have been
installed in the incubator/cooler on the China Space Station. The duration of our
experiment is 31 days for organoids exposed to the natural spaceflight environment
(microgravity and cosmic radiation), 31 days for organoids exposed to microgravity
under the tantalum cover designed to protect our samples from cosmic radiation,
and minimum 10 days for organoids exposed to cosmic radiation and Earth gravity
with the use of the 1 g centrifuge. Dosimeters will be used to read the radiation level
for the duration of the experiment.
The cell nourishment and fixation will be automated and pre-programmed
according to experimental needs. Subsequent cold stowage of the fixed samples will
be required at the end of the experiment. After completion of the mission and
successful environmentally controlled return to the ground, our units will be
transported to our laboratories for organoid subcloning, sequencing, and
genotyping as described above.
6. Impact
Tumors in Space is a cancer research project at the intersection of stem-cell
biology and space technology that will acquire new knowledge on cancer etiology
due to the influence of the spaceflight environment. By conducting cutting-edge
laboratory-based research in orbit and testing our two novel hypotheses, we are
challenging the current scientific paradigm. We aim to spark curiosity and inspire
the public by conducting excellent science at the forefront of international research
in collaboration with the United Nations Office for Outer Space Affairs (UNOOSA)
and the China Manned Space Agency.
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The Sustainable Development Goals: The UNOOSA works to promote the peaceful
use of outer space for the benefit of humankind. This includes a collaboration with
the CMSA to fly international experiments on board the China Space Station. The 17
Sustainable Development Goals (Figure 8) were adopted by the United Nations in
2015 [31] as a global call for action to improve environmental conditions on Earth
and socioeconomic as well as health conditions for all humanity. Tumors in Space has
a role to play in the attainment of the Sustainable Development Goals by 2030
through the peaceful and collaborative use of outer space to ensure healthy lives and
promote well-being for all people of all ages.
Science communication in the public domain: Science funded by the people is meant
to be delivered to the people, and this is one of the goals of Tumors in Space.We have
designed a comprehensive science communication and research dissemination plan.
The main feature of our plan is our project website that will include open access to our
research results and scientific publications, research highlights, a color photo library,
team bio-sketches, blog posts, and social media feeds (e.g., Twitter), as well as an up-
to-date list of all interviews and feature articles for the Tumors in Space project. Our
efforts also include educational outreach focused on girls and marginalized youth.
7. Conclusions
This chapter provides an overview of the Tumors in Space experiment beginning
with the scientific evidence upon which the hypotheses are based. The seven main
steps in our spaceflight preparation have been presented including ethics and regu-
latory affairs, laboratory methods, spaceflight hardware design, ground-based
experiments (radiation and simulated microgravity), as well as sounding rocket and
aircraft parabolic flight experiments. This takes us to the final preparations for our
spaceflight experiment set to be launched to the China Space Station in 2025.
Finally, some brief notes on the importance of the Sustainable Development Goals
and communication of science in the public domain have been provided. To end
this chapter, we provide a note of encouragement. Do share this chapter widely in
the spirit of open access to scientific knowledge. We welcome you to follow our
journey into orbit as we reach for our ultimate goal: to make novel contributions to
cancer risk prediction, diagnostics, and therapeutics for human health during short-
and long-duration space missions and public health on Earth.
Figure 8.
The 17 Sustainable Development Goals (credit: United Nations).
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